language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
NEOGNEOG

$10.94

+0.16
arrow_drop_up1.48%
Market closed·update13 Feb 2026 21:00

$11.01

+0.07
arrow_drop_up0.64%
Post-market·update13 Feb 2026 22:13
Day's Range
10.74-11.15
52-week Range
3.87-11.15

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2026-01-08
Next Earnings TimeBefore Market Open
Volume4.28M
Average Volume 30d3.94M

AI NEOG Summary

Powered by LiveAI
💰
-2.3
Valuation (P/E Ratio)
Negative P/E due to recent losses
📈
0.1237
Revenue Growth (YoY)
Significant revenue increase
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Hold
65

Neogen Corporation exhibits a mixed investment profile. While its core business in food and animal safety offers a stable, albeit slow-growth, market, current financial performance and technical indicators suggest a holding rather than a strong buy or sell recommendation. The company faces profitability challenges and mixed technical signals.

Neutral

Thematic

60

Neogen operates in the essential sectors of food and animal safety, benefiting from increasing global demand for safe food and animal welfare. However, its growth may be slower compared to high-tech sectors, and it lacks strong thematic tailwinds like AI or renewable energy.

Neutral

Fundamental

58

Neogen's financials present a mixed picture. While revenue has grown, profitability has been inconsistent, with recent periods showing net losses. The balance sheet appears manageable, but cash flow from operations is a concern.

Bullish

Technical

70

Short-term technical indicators suggest a potential upward bias, with most moving averages indicating 'Buy' signals. However, RSI is in neutral territory, and broader trends over the past year have been negative.

FactorScore
Food Safety Demand75
Animal Health & Welfare70
Genomics & Diagnostics65
Market Disruption Potential40
Regulatory Environment60
FactorScore
Valuation60
Profitability10
Growth70
Balance Sheet Health70
Cash Flow20
FactorScore
Trend Analysis60
Momentum50
Short-term Moving Averages80
Price Action40
Volume Trends60

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (6)

Current Price & Performance chevron_right

Positive Price Action

The current price is $4.955, which is up 0.71% for the day. The 5-day performance is -5.08%, 1-month performance is 0.3%, indicating recent stability after a decline.

Key Stats & Financial Health chevron_right

Improving Free Cash Flow

Free cash flow has improved from -$76.16M in 2024Q2 to -$24.73M in 2023Q2, showing a positive trend in cash generation.

Show More 🔒
thumb_down

Bearish Points (8)

Earnings Performance chevron_right

Negative EPS Trend

EPS has been negative for recent periods (e.g., -0.9% in 2024Q1, -2.3% in 2024Q2), indicating ongoing profitability challenges.

Valuation chevron_right

Negative P/E Ratio

The trailing Price-to-Earnings (P/E) ratio is -2.2, and forward P/E ratios are also negative or extremely high, signaling that the company is not currently profitable on a per-share basis.

Show More 🔒

Calendar

July 2025

29

Next Earnings Date

EPS Est.
Revenue Est.

H: $0.10

A: $0.09

L: $0.08

H: 225.00M

A: 222.53M

L: 221.00M

Profile

Websiteneogen.com
Employees (FY)2.92K
ISIN-
FIGI-

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared food products and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. The company was incorporated in 1981 and is headquartered in Lansing, Michigan.

Seasonals

2025
2024
2023
2022
2021

Price Target

7.50 USD

The 39 analysts offering 1 year price forecasts for NEOG have a max estimate of 10.00 and a min estimate of 5.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
201M (92.79%)
Closely held shares
15.7M (7.21%)
217M
Free Float shares
201M (92.79%)
Closely held shares
15.7M (7.21%)

Capital Structure

Market cap
1.11B
Debt
890.84M
Minority interest
0.00
Cash & equivalents
170.61M
Enterprise value
1.83B

Valuation - Summary

Market Cap
1.11B
Net income
-480M(-43.18%)
Revenue
669M(60.22%)
1.11B
Market Cap
1.11B
Net income
-480M(-43.18%)
Revenue
669M(60.22%)
Price to earning ratio (P/E)-2.30x
Price to sales ratio (P/S)1.70x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
924.22M
COGS
460.32M
Gross Profit
463.9M
OpEx
405.24M
Operating Income
58.66M
Other & Taxes
68.08M
Net Income
-9.42M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒